Workflow
Viking Therapeutics(VKTX) - 2024 Q3 - Quarterly Report
VKTXViking Therapeutics(VKTX)2024-10-23 21:00
Transcript

Research and Development - The company incurred 70.7millioninresearchanddevelopmentexpensesduringtheninemonthsendedSeptember30,2024,primarilyforVK2735,VK2809,andVK0214clinicaltrials[88].−VK2735demonstratedstatisticallysignificantmeanbodyweightreductionsofupto14.770.7 million in research and development expenses during the nine months ended September 30, 2024, primarily for VK2735, VK2809, and VK0214 clinical trials [88]. - VK2735 demonstrated statistically significant mean body weight reductions of up to 14.7% from baseline in the Phase 2 VENTURE study after 13 weeks [78]. - VK2809 achieved a primary endpoint in the VOYAGE study, with significant reductions in liver fat content from baseline to Week 12 compared to placebo [80]. - In the VOYAGE study, up to 75% of VK2809-treated patients achieved MASH/NASH resolution with no worsening of fibrosis, compared to 29% for placebo (p=0.0001) [81]. - VK0214 showed significant reductions in plasma levels of very long-chain fatty acids in a Phase 1b clinical trial, indicating its potential efficacy for X-ALD [85]. - The Phase 2 VENTURE study for VK2735 enrolled adults with obesity or overweight, with a primary endpoint focused on percent change in body weight [78]. - The company plans to advance VK2735 into Phase 3 development based on FDA feedback following positive Phase 2 results [78]. Financial Performance - The company has not generated any revenue to date and does not expect to until drug candidates are approved and commercialized [88]. - Research and development expenses for Q3 2024 increased by 24.0% to 22.8 million compared to 18.4millioninQ32023,primarilyduetohighermanufacturingcostsandstock−basedcompensation[94].−GeneralandadministrativeexpensesforQ32024roseby55.018.4 million in Q3 2023, primarily due to higher manufacturing costs and stock-based compensation [94]. - General and administrative expenses for Q3 2024 rose by 55.0% to 13.8 million from 8.9millioninQ32023,mainlydrivenbyincreasedstock−basedcompensationandlegalservices[95].−TotalotherincomeforQ32024was8.9 million in Q3 2023, mainly driven by increased stock-based compensation and legal services [95]. - Total other income for Q3 2024 was 11.6 million, a significant increase of 145.5% from 4.7millioninQ32023,primarilyduetointerestincome[96].−ResearchanddevelopmentexpensesfortheninemonthsendedSeptember30,2024,totaled4.7 million in Q3 2023, primarily due to interest income [96]. - Research and development expenses for the nine months ended September 30, 2024, totaled 70.7 million, reflecting a 63.2% increase from 43.3millioninthesameperiodof2023[97].−GeneralandadministrativeexpensesfortheninemonthsendedSeptember30,2024,were43.3 million in the same period of 2023 [97]. - General and administrative expenses for the nine months ended September 30, 2024, were 34.0 million, up 20.5% from 28.2millionintheprioryear[98].−TotalotherincomefortheninemonthsendedSeptember30,2024,reached28.2 million in the prior year [98]. - Total other income for the nine months ended September 30, 2024, reached 30.1 million, a 194.0% increase from 10.3millioninthesameperiodof2023[99].CashandInvestments−AsofSeptember30,2024,thecompanyhadcash,cashequivalents,andshort−terminvestmentsof10.3 million in the same period of 2023 [99]. Cash and Investments - As of September 30, 2024, the company had cash, cash equivalents, and short-term investments of 930.4 million, expected to fund operations through at least December 31, 2025 [100]. - Cash used in operating activities for the nine months ended September 30, 2024, was 56.6million,comparedto56.6 million, compared to 55.7 million in the same period of 2023 [108][109]. - Cash used in investing activities for the nine months ended September 30, 2024, was 560.0million,significantlyhigherthan560.0 million, significantly higher than 214.8 million in the same period of 2023 [110]. - Cash provided by financing activities for the nine months ended September 30, 2024, was 611.5million,comparedto611.5 million, compared to 271.2 million in the same period of 2023, primarily from stock offerings [111]. - As of September 30, 2024, cash and cash equivalents totaled 50,347,000,downfrom50,347,000, down from 55,516,000 on December 31, 2023 [117]. - Short-term investments available-for-sale increased significantly to 880,093,000from880,093,000 from 306,563,000 [117]. - Total cash and short-term investments reached 930,440,000,comparedto930,440,000, compared to 362,079,000 at the end of 2023 [117]. - A 10% increase or decrease in short-term interest rates would result in an annual interest income change of approximately $1.4 million [117]. - The investment portfolio is primarily composed of U.S. government securities, investment-grade corporate bonds, and money market funds [114]. - The company has implemented guidelines to limit the term-to-maturity of its investment instruments to manage interest rate risk [115]. - Interest income from cash and short-term investments will vary with fluctuations in U.S. interest rates [116]. - The company does not believe that the fair value of its investments has a material exposure to interest rate risk due to the conservative nature of the instruments [115]. - The investment portfolio is used to preserve capital, provide liquidity, and earn returns aligned with the company's risk appetite [114]. - The company accounts for its securities as available-for-sale, realizing gains or losses only upon sale or credit loss [115].